Gonadorelin

Shop Gonadorelin
Code ths10 applied at checkout

Also called: Gonadotropin releasing hormone, Gonadotropin-Releasing Hormone (GnRH) Human, Synthetic, Gonadotropin-Releasing Hormone (GnRH1)

By The Health Stacks Research TeamUpdated September 19, 2026

Gonadorelin is a medicine that copies a natural body signal. This signal tells a part of the brain to wake up. It is given as a shot, usually by a doctor. Some men's health clinics use it for men whose male hormone levels have dropped with age.

When gonadorelin goes in, it tells the brain's control center to send a message. That message tells the body to make more of its own male hormone. This can help with low energy, weak muscles, mood problems, and sleep trouble that come with low hormones. It may work a lot like direct hormone replacement shots.

Doctors do not know everything about it yet. Most of what we know comes from clinics that use it, not from big careful studies. A shot can cause soreness or other reactions, so it should only be used with a doctor's care. More research is needed to be sure how well it works and how safe it is over time.

ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. Verified confidence80–100 — backed by strong, well-corroborated sources (peer-reviewed research, clinical guidelines). Our highest confidence tier.

Benefits

What Gonadorelin Helps With

The benefits people report — backed by research.

Reproductive & hormonal (16)

Pulsatile GnRH stimulates biosynthesis and secretion of LH and FSH from pituitary gonadotropes 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Continuous GnRH infusion suppresses LH and FSH secretion, exploited clinically with long-acting agonists to treat endometriosis, leiomyomas, breast cancer, and prostate cancer 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Pulsatile GnRH is the primary hormonal activator of the reproductive axis in all vertebrates 92/100Rated 92/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GnRH regulates reproduction across animal species, with N and C termini conserved as functional domains for receptor binding and activation 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liver health 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GnRH stimulates release of luteinizing hormone as a gonadotropin-releasing decapeptide 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GnRH cytotoxins examined for gonadotrope ablation as non-surgical sterilization in animals showed low and/or transient effects 78/100Rated 78/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GnRH-targeted approach could suppress reproductive axis with multi-layer specificity, offering alternatives to GnRH super-analogs and GnRH-conjugated toxins (low/tr 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Induction of spermatogenesis in hypogonadism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement of pregnancy rates in cows with low body condition 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Used as gonadal control hormones for numerous indications 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Gonadotropin-Releasinghormone used as gonadal control hormones for numerous indications 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Androgens used for substitution therapy in male hypogonadism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Can successfully induce spermatogenesis in male hypogonadism patients wishing to preserve fertility 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction of heavy menstrual bleeding 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of uterine fibroids 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Cancer / tumor (4)

GnRH-I and its superagonistic analogs reduce proliferation of human ovarian cancer cell lines in a time- and dose-dependent manner 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Approximately 80% of ovarian cancers express high-affinity GnRH-I receptors, suggesting a local autocrine regulatory system 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GnRH-conjugated toxins show anti-proliferative activity against GnRHR/LHRH-receptor-expressing cancers and are in clinical trials 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Cetrorelix has antiproliferative effects comparable to GnRH-I agonists in most ovarian cancer cell lines 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Musculoskeletal (2)

Modulation of sulfated neurosteroid production 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Muscle recovery 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Energy & mitochondrial (1)

Energy metabolism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

More reported benefits (5)

GnRH II shows high binding affinity due to preconfigured type II' beta-turn conformation via intramolecular interactions 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →No substitution with a natural amino acid in any position of GnRH improves binding potency 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Stimulation of sexual activity 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →BDNF gene transfer into hypothalamic ARC and VMH increases oxygen consumption indicating elevated resting metabolic rate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →POMC gene rescue in the arcuate nucleus mitigates age-dependent metabolic dysfunction 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Free: The Peptide Stack Cheat-Sheet

You just read the research on Gonadorelin. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.

No spam. Unsubscribe anytime.

Safety

Known Side Effects

Adverse effects reported in the research and by community use.

  • No negative impact on sperm motility (Fish)Mild 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pubmed.ncbi.nlm.nih.gov
  • Galaktorrhö unter SSRI-EinnahmeMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ springermedizin.de

Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.

Get Gonadorelin

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Shop Gonadorelin
Code ths10 applied at checkout

Evidence

Research Citations (7)

Every claim above traces back to a source you can check — here are 7 of them.

  • PubChem - Compound - Gonadorelin

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review

    2014 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • LH and FSH response to gonadotropin releasing hormone (GnRH) in normospermic, oligospermic and azoospermic men.

    1978 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Gonadorelin | C55H75N17O13 | CID 638793 - PubChem

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • The gonadotropin-releasing hormone (Gnrh) gene maps to mouse chromosome 14 and identifies a homologous region on human chromosome 8

    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone

    85/100Rated 85/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Evolution of gonadotropin-releasing hormone (GnRH) structure and its receptor

    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

Timeline

History & Milestones

Key moments in Gonadorelin’s research and regulatory timeline — sourced and dated.

  1. Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing HormonePublicationJul 1, 2021
    Related:Gonadorelin
    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  2. Putative Gonadotropin-Releasing Hormone Agonist Therapy and DementiaPublicationJan 1, 2018
    Related:Gonadorelin
    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  3. Gonadotropin-releasing hormone agonist treatment in postmenopausal womenPublicationMay 1, 2011
    Related:Gonadorelin
    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  4. GnRH agonists: gonadorelin, leuprolide and nafarelinPublicationNov 1, 1991
    Related:Gonadorelin
    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  5. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in menPublicationSep 1, 1987
    Related:Gonadorelin
    90/100Rated 90/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

Wondering how Gonadorelin pricing compares across suppliers? Our original market data shows the full picture.

See the State of the Peptide Market 2026 →

Related on The Health Stacks

Compare

Gonadorelin vs Kisspeptin

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.